newshome.com
域名年龄: 21年4天HTTP/1.1 301 永久重定向 访问时间:2015年06月17日 14:24:31 目标网址:http://newscentre.boehringer-ingelheim.com/ 文件大小:251 Keep-Alive: timeout=5, max=100 连接:Keep-Alive 类型:text/html; charset=iso-8859-1 设置Cookie:BIGipServerRD_010_POOL_STD_94.100.253.195_8080=rd10o00000000000000000000ffff0a02a245o8080; path=/ HTTP/1.1 200 OK 访问时间:2015年06月17日 14:24:31 修改日期:2015年06月17日 07:08:39 接受单位:字节 类型:text/html; charset=UTF-8 node: Metis 文件大小:59437 Keep-Alive: timeout=5, max=100 连接:Keep-Alive 设置Cookie:BIGipServerRD_010_POOL_STD_94.100.253.195_8080=rd10o00000000000000000000ffff0a02a245o8080; path=/ 网站编码:UTF-8
HomeCountry websitesContactFAQFacebookTwitterSearchSubmitHomePress ReleasesEvents and InitiativesEducation Huboncologymetabolismrespiratorycardiovascular-strokeImage LibraryRLS - Restless Legs SyndromStroke Prevention in AFVenous ThromboembolismParkinson's DiseaseHistoryManagementManufacturingResearch & DevelopmentCopdDiabetesHIV / Aids BuildingsMedia Contacts This website is intended for journalists outside the US/UK/Canada, who are interested in media information from Boehringer Ingelheim.Latest Press Releases16.06.2015New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers08.06.2015Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care08.06.2015Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA - Type 2 diabetes03.06.2015NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication03.06.2015Respimat® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim31.05.2015ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung28.05.2015Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union28.05.2015Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropathy in Pima Indians27.05.2015Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific SessionsTop Stories Myths & Misconceptions - The Anticoagulation Debate #TellingMyStory for Stroke Awareness MonthprevnextEvents and InitiativesASCO 201514 May 2015Education Hub Tweets about "#oncology" INFOGRAPHICNintedanib* Lume-Lung 1 Clinical TrialINFOGRAPHICAfatinib* Lux-Lung 3 & 6 Clinical TrialsTweets from @Boehringer Back to topSitemapTerms of useRSS FeedPrint pageRecommend© 2010 - 2014 Boehringer Ingelheim GmbH All rights reservedLegal Text: This text contains legal text that has to be visible on all pages of the website. It is maintained in the client configuration. If it is required to have a special formatting for the legal text, it is recommend to insert that formatted text as an image in the respective entry of client configuration. Our company Corporate homeAbout usAnnual reportAnnual press conferenceOther News CentresUSUKOur website by countryOur Countries A-ZArgentinaAustriaAustraliaBahrainBelarusBelgiumBosnia and HerzegovinaBrazilBulgariaCanadaChileChinaColombiaCroatiaCyprusCzech RepublicDenmarkEcuadorEgyptEstoniaEthiopiaFinlandFranceGermanyGermany HeadquartersGreeceGhanaHong Kong Hungary India Indonesia Iraq Irland Italy Japan Jordan Kenya Kuweit Latvia Lebanon Libya Lithuania Macedoni
© 2010 - 2020 网站综合信息查询 同IP网站查询 相关类似网站查询 网站备案查询网站地图 最新查询 最近更新 优秀网站 热门网站 全部网站 同IP查询 备案查询
2024-12-04 15:53, Process in 0.0057 second.